Article Abstract

Rebuttal from Dr Nestle and Dr Belderbos

Authors: Ursula Nestle, José Belderbos

Abstract

We fully agree that in a case when a patient with a T2N0M0 NSCLC central in the hilum has no other curative treatment option and is not eligible for conventionally fractionated radiotherapy, we can discuss with him/her the potential risk of SBRT and the weakness of the available data and may offer this treatment when the patient agrees to bear this risk.